Literature DB >> 8623935

Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1.

F A Offner1, H Feichtinger, S Stadlmann, P Obrist, C Marth, P Klingler, B Grage, M Schmahl, C Knabbe.   

Abstract

Peritoneal mesothelial cells are uniquely located to regulate cellular events in the peritoneal cavity and are a potentially important source for various cytokines. The present study was designed to elucidate the capacity of human peritoneal mesothelial cells (HPMCs) to synthesize and secrete the transforming growth factor (TGF)-beta isoforms 1, 2, and 3 and to characterize their regulation by inflammatory cytokines. HPMCs constitutively released appreciable amounts of TGF-beta 1 and low amounts of TGF-beta 2 as detected by specific immunoassays. TGF-beta 1 levels secreted within 48 hours (45 +/- 8.9 pg/10(5) cells) were 60-fold higher than TGF-beta 2 levels (0.9 +/- 0.1 pg/10(5) cells), respectively. Treatment of HPMCs with interleukin (IL)-1 beta (10 ng/ml) resulted in a significant increase of both TGF-beta 1 (mean, 5-fold; P < 0.001) and TGF-beta 2 (mean, 6-fold; P < 0.01) generation. After 48 hours of IL-1 beta treatment the levels were 185 +/- 17.1 pg/10(5) cells for TGF-beta 1 and 5.3 +/- 1.5 pg/10(5) cells for TGF-beta 2, respectively. Neither tumor necrosis factor (TNF)-alpha nor interferon (IFN)-gamma (both 10 ng/ml) affected TGF-beta 1 or TGF-beta 2 synthesis by HPMCs. TGF-beta 3 could not be detected in any of the supernatant media. Stimulation of HPMCs with IL-1 beta increased steady-state levels of TGF-beta 1- and TGF-beta 2-specific mRNA. Western blot analysis of supernatants revealed the presence of an immunoreactive band at 25 kd. Indirect competition assays confirmed receptor-binding activity of HPMC-derived TGF-beta. Appreciable amounts of TGF-beta were present in a bioactive form. Our results demonstrate that HPMCs synthesize the TGF-beta isoforms 1 and 2 and that the levels of mRNA and protein release can be up-regulated by the proinflammatory cytokine IL-1 beta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623935      PMCID: PMC1861567     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix.

Authors:  R A Ignotz; J Massagué
Journal:  J Biol Chem       Date:  1986-03-25       Impact factor: 5.157

2.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

Authors:  S M Wahl; D A Hunt; L M Wakefield; N McCartney-Francis; L M Wahl; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor.

Authors:  R F Tucker; G D Shipley; H L Moses; R W Holley
Journal:  Science       Date:  1984-11-09       Impact factor: 47.728

4.  Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin.

Authors:  S V Suggs; R B Wallace; T Hirose; E H Kawashima; K Itakura
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

5.  Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes.

Authors:  B Y Li; D Mohanraj; M C Olson; M Moradi; L Twiggs; L F Carson; S Ramakrishnan
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

6.  IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells.

Authors:  F A Offner; P Obrist; S Stadlmann; H Feichtinger; P Klingler; M Herold; H Zwierzina; A Hittmair; G Mikuz; B Abendstein
Journal:  Cytokine       Date:  1995-08       Impact factor: 3.861

7.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

8.  Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

Authors:  C Knabbe; M E Lippman; L M Wakefield; K C Flanders; A Kasid; R Derynck; R B Dickson
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

9.  Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

Authors:  T Espevik; I S Figari; M R Shalaby; G A Lackides; G D Lewis; H M Shepard; M A Palladino
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  14 in total

1.  Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

Authors:  M V Cronauer; S Stadlmann; H Klocker; B Abendstein; I E Eder; H Rogatsch; A G Zeimet; C Marth; F A Offner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury.

Authors:  Yi-Ting Chen; Yu-Ting Chang; Szu-Yu Pan; Yu-Hsiang Chou; Fan-Chi Chang; Pei-Ying Yeh; Yuan-Hung Liu; Wen-Chih Chiang; Yung-Ming Chen; Kwan-Dun Wu; Tun-Jun Tsai; Jeremy S Duffield; Shuei-Liong Lin
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

3.  Increased levels of transforming growth factor beta 1 and basic fibroblast growth factor in patients on CAPD: a study during non-infected steady state and peritonitis.

Authors:  N C Mlambo; B Hylander; A Brauner
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

4.  The inhibition of tumor cell adhesion on human mesothelial cells (HOMC) by phospholipids in vitro.

Authors:  M Jansen; P Lynen Jansen; J Otto; T Kirtil; S Neuss; K-H Treutner; V Schumpelick
Journal:  Langenbecks Arch Surg       Date:  2006-03-14       Impact factor: 3.445

5.  Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Sylvia Stadlmann; Ruth Raffeiner; Albert Amberger; Raimund Margreiter; Alain Gustave Zeimet; Burkhardt Abendstein; Patrizia Lucia Moser; Gregor Mikuz; Bernd Klosterhalfen; Felix Albert Offner
Journal:  Virchows Arch       Date:  2003-07-26       Impact factor: 4.064

6.  Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10.

Authors:  Akira Onishi; Tetsu Akimoto; Masashi Urabe; Ichiro Hirahara; Shigeaki Muto; Keiya Ozawa; Daisuke Nagata; Eiji Kusano
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

7.  The Role of Interleukin-1 Genotype in the Association between Coronary Heart Disease and Periodontitis in a Syrian Population.

Authors:  Lina Bashour; Razan Khattab; Elham Harfoush
Journal:  ISRN Dent       Date:  2013-04-14

8.  Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?

Authors:  Jesús Loureiro; Guadalupe Gónzalez-Mateo; José Jimenez-Heffernan; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera Peralta
Journal:  Int J Nephrol       Date:  2013-02-10

9.  Paracrine effects of transplanted mesothelial cells isolated from temperature-sensitive SV40 large T-antigen gene transgenic rats during peritoneal repair.

Authors:  Reo Kanda; Chieko Hamada; Kayo Kaneko; Takanori Nakano; Keiichi Wakabayashi; Kazuaki Hara; Hiroaki Io; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2013-09-29       Impact factor: 5.992

10.  The peritoneum is both a source and target of TGF-β in women with endometriosis.

Authors:  Vicky J Young; Jeremy K Brown; Philippa T K Saunders; W Colin Duncan; Andrew W Horne
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.